All News
Dietary Improvement in Psoriatic Arthritis
The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.
Read Article
Now Available: TNR - Psoriatic Arthritis Journal Club
A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.
Read Article
Male vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Read Article
Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2
Links:
Dr. John Cush RheumNow ( View Tweet)
Open label, RCT compared triple DMARD Rx adding either LEF (MLH) or SSZ (MSH) to MTX+HCQ in 136 RA pts. Both were equally effective (non-inferior), 61.7% & 64.7% patients (p = 0.8) at wk 24. AE were also equal (15 vs 21 AE). https://t.co/cxdeBfo6XA
Links:
Dr. John Cush RheumNow ( View Tweet)
2 studies from NKF meeting shows gout occurs in 13.5% of CKD on dialysis; and seen in 17-28% of Stg 3,4 CKD pts. CKD w/ Gout has more bone/mineral Dz (40 vs 26%), CHF (21 vs 14%), DJD (17 vs 9%); >1/3 NOT on urate lowering therapy https://t.co/sn40xqxRyg https://t.co/ewb0tpWukw
Dr. John Cush RheumNow ( View Tweet)
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Copenhagen study of COVID & Rheum disease (AIRD)
▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%)
▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6)
▶️ IgG Abs increased if AIRD pt hospitalized
https://t.co/VtERRZsGb8 https://t.co/ZwdfNJaAS7
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/0uKAKJVxri https://t.co/KuvEA2pzrg
Links:
Dr. John Cush RheumNow ( View Tweet)
In #rheumatology ,the longer you see pts,the more they rely on you for issues related to their disease, including
➡️ Dental/mental Health
➡️ Nutrition/exercise/sleep
➡️ PT/OT/rehab
Looking for resources pertaining to rheumatology to self educate.
#RheumTwitter #MedTwitter
Tanmayee Bichile, MD BichileT ( View Tweet)
Register for Tuesday Night Rheumatology today! Join us as we discuss the controversies in PsA when it comes to diagnosis, treatment strategies, therapeutics and more.
https://t.co/YXAmzvPfeK https://t.co/jtSd0Ig5IT
Links:
Dr. John Cush RheumNow ( View Tweet)
Administrative Claims data from British Columbia studied 100,358 OA pts and compared tramadol v NSAIDs. Tramadol was associated with higher All-cause mortality (HRs,1.2 to 1.5), more VTE (v diclofenac, HR 1.7), more hip Fx (HR 1.6) https://t.co/5Lei6Lgtpf
Links:
Dr. John Cush RheumNow ( View Tweet)
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor
https://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a
Links:
Dr. John Cush RheumNow ( View Tweet)
No Benefit to More Intensive Urate Lowering in Gout
While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.
https://t.co/uag4fJ4FSi https://t.co/djniwFl491
Links:
Dr. John Cush RheumNow ( View Tweet)
Copenhagen study of COVID & Rheum disease (AIRD)
▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%)
▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6)
▶️ IgG Abs increased if AIRD pt hospitalized
https://t.co/WYXbt2FJJi https://t.co/K2NGJsKVVc
Links:
Dr. John Cush RheumNow ( View Tweet)
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA
37 RCTs = 14.115 PsA pts
◾️ bDMARDs > PBO
◾️ bDMARDs = MTX (or Tofa)
◾️ bDMARDs + MTX > MTX
https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK
Links:
Dr. John Cush RheumNow ( View Tweet)
Downward Effects! Real world data from 22,934 UK #RA pts starting 1st b/tsDMARD shows DAS remission/LDA achieved in 17% following 1st line, 13% 2nd, & 8-13% with 3rd thru 6th DMARD. (LDA in 29% 1st line, 23% 2nd, 17–22% 3rd thru 6th) https://t.co/cZt0BvhK6I https://t.co/blemgbDoN8
Links:
Dr. John Cush RheumNow ( View Tweet)
Despite COVID, revenues for half of top 20 pharma companies grew 10-40% in
2021
Revenues (billions)
1 J&J $97
2 Pfizer $81
3 Roche $62
4 Abbvie $56
5 Novartis $51
6 Merck $48
7 BMS $46
8 GSK $46
9 Sanofi $44
10 AZ $37
https://t.co/rSovxIXOId https://t.co/GuKIBYoML6
Links:
Dr. John Cush RheumNow ( View Tweet)
Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/Om8CwbmlgN https://t.co/872E7HGOp2
Links:
Dr. John Cush RheumNow ( View Tweet)